OUR MISSION

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.
TB IS THE WORLD'S DEADLIEST INFECTIOUS DISEASE

TB is a global pandemic.

- In 2018, more than 10 million people developed active TB, and about 1.5 million people died from it—including about 205,000 children.
- It is also a leading cause of death of people living with HIV/AIDS.
- TB is learning how to resist the antibiotics currently used to treat it.
- Drug-resistant TB accounts for about 1 in 3 deaths from antimicrobial resistance.

TB is found everywhere in the world. The World Health Organization has identified 30 “high burden” countries (in dark blue) that have the most people with TB, drug-resistant TB, or TB-HIV coinfections.
TB is a difficult disease to cure.

- Current TB treatments take too long to cure, are too complicated to administer and can be toxic.
- Even for drug-sensitive TB (the simplest form of the disease), treatment requires taking a combination of harsh antibiotics for at least six months.
- Treatments for drug-resistant forms of TB can exceed 14,000 pills and can last 18 months or longer.
- Some of the most common side effects of treatment for drug-resistant TB include hearing loss, depression or psychosis, and kidney damage.
NOW APPROVED

In August 2019, TB Alliance received approval for a new treatment regimen for people with highly drug-resistant forms of TB.

 Approval of this treatment represents hope for the people suffering from these highly drug-resistant forms of the world’s deadliest infectious disease.”

—Mel Spigelman, President and CEO of TB Alliance
TB Alliance manages the largest pipeline of new TB drugs in history for all forms of the disease and has advanced multiple products to market. We prioritize projects that have the potential to have the greatest impact, including:

- Shorter, simpler and safer treatment, with better adherence and fewer side effects;
- Reduced burden on TB patients, programs and health care systems;
- Affordable for all settings; and
- Improved cure rates and patient experience.

Today, our research portfolio includes several novel TB drug regimens in late-stage development, improved treatments for children and a robust discovery program—more than 30 active projects in all.
TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, European & Developing Countries Clinical Trials Partnership, Foreign, Commonwealth and Development Office (United Kingdom), Germany’s Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, Rockefeller Foundation, and the United States Agency for International Development.